|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
US7651689B2
(en)
*
|
2002-11-15 |
2010-01-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Methods of applying ionization radiation for therapy of infections
|
|
EP1572242B1
(en)
|
2002-12-13 |
2014-04-16 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
US7878978B2
(en)
*
|
2004-03-18 |
2011-02-01 |
University Of Pittsburgh- Of The Commonwealth System Of Higher Education |
Use of relaxin to increase arterial compliance
|
|
US20110166319A1
(en)
*
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
EP3539572A1
(en)
|
2005-08-24 |
2019-09-18 |
ImmunoGen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
|
BRPI0711586A2
(pt)
*
|
2006-05-15 |
2011-11-16 |
Immunonomedics, Inc. |
método para tratamento de infecção por hiv em um indivìduo, método para imagem latente detectar ou diagnosticar a infecção por hiv em um indivìduo, composição
|
|
US8034396B2
(en)
*
|
2008-04-01 |
2011-10-11 |
Tyco Healthcare Group Lp |
Bioadhesive composition formed using click chemistry
|
|
EP2276506A4
(en)
|
2008-04-30 |
2014-05-07 |
Immunogen Inc |
EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
|
|
US20100009390A1
(en)
*
|
2008-05-09 |
2010-01-14 |
The Regents Of The University Of California |
Mutant antibodies with high affinity for egfr
|
|
US20100008978A1
(en)
*
|
2008-05-09 |
2010-01-14 |
The Regents Of The University Of California |
Nanoparticles effective for internalization into cells
|
|
JP2011520902A
(ja)
*
|
2008-05-16 |
2011-07-21 |
コーセラ，インコーポレーテッド |
創傷の治癒を促進する方法
|
|
EP2305309A2
(en)
|
2008-06-13 |
2011-04-06 |
Proyecto de Biomedicina Cima, S.L. |
Conjugates for the administration of biologically active compounds
|
|
US20110287036A1
(en)
*
|
2008-11-17 |
2011-11-24 |
Riken |
Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
|
|
EP2374813A1
(en)
|
2008-12-03 |
2011-10-12 |
Proyecto de Biomedicina Cima, S.L. |
Use of phenol-soluble modulins for vaccine development
|
|
EP3912643B8
(en)
*
|
2009-02-13 |
2023-08-23 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
WO2010095056A2
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Medical devices with an activated coating
|
|
US8535477B2
(en)
|
2009-02-21 |
2013-09-17 |
Sofradim Production |
Medical devices incorporating functional adhesives
|
|
EP2398524B1
(en)
|
2009-02-21 |
2017-07-12 |
Covidien LP |
Medical devices having activated surfaces
|
|
WO2010095045A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Amphiphilic compounds and self-assembling compositions made therefrom
|
|
CA2753188A1
(en)
|
2009-02-21 |
2010-08-26 |
Tyco Healthcare Group Lp |
Medical devices having activated surfaces
|
|
US9523159B2
(en)
|
2009-02-21 |
2016-12-20 |
Covidien Lp |
Crosslinked fibers and method of making same using UV radiation
|
|
WO2010095049A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Crosslinked fibers and method of making same by extrusion
|
|
US8512728B2
(en)
|
2009-02-21 |
2013-08-20 |
Sofradim Production |
Method of forming a medical device on biological tissue
|
|
EP2398584A2
(en)
|
2009-02-21 |
2011-12-28 |
Sofradim Production |
Apparatus and method of reaching polymers by exposure to uv radiation to produce injectable medical devices
|
|
US8663689B2
(en)
*
|
2009-02-21 |
2014-03-04 |
Sofradim Production |
Functionalized adhesive medical gel
|
|
US8877170B2
(en)
*
|
2009-02-21 |
2014-11-04 |
Sofradim Production |
Medical device with inflammatory response-reducing coating
|
|
EP2398519A2
(en)
|
2009-02-21 |
2011-12-28 |
Sofradim Production |
Compounds and medical devices activated with solvophobic linkers
|
|
US9039979B2
(en)
|
2009-02-21 |
2015-05-26 |
Sofradim Production |
Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
|
|
US8968733B2
(en)
*
|
2009-02-21 |
2015-03-03 |
Sofradim Production |
Functionalized surgical adhesives
|
|
CA2760771A1
(en)
*
|
2009-05-04 |
2010-11-11 |
Intezyne Technologies, Incorporated |
Polymer micelles containing sn-38 for the treatment of cancer
|
|
EP2258398A1
(en)
|
2009-05-26 |
2010-12-08 |
Araclón Biotech, S. L. |
Albumin-amyloid peptide conjugates and uses thereof
|
|
BRPI1010620B8
(pt)
|
2009-06-03 |
2021-05-25 |
Immunogen Inc |
métodos de conjugação
|
|
US8853151B2
(en)
|
2009-06-30 |
2014-10-07 |
The Regents Of The University Of Michigan |
Pro-drug complexes and related methods of use
|
|
BR112012000536A2
(pt)
|
2009-07-08 |
2020-08-11 |
Kymab Limited |
métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US20120237535A1
(en)
|
2009-09-11 |
2012-09-20 |
Proyecto De Biomedicina Cima, S.L. |
Therapeutic Compositions For The Treatment of HPV-Induced Diseases
|
|
ES2978177T3
(es)
|
2009-12-02 |
2024-09-06 |
Immunomedics Inc |
Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
|
|
US20120259099A1
(en)
*
|
2009-12-15 |
2012-10-11 |
MuHyeon CHOE |
Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
CA2794336A1
(en)
*
|
2010-03-25 |
2011-09-29 |
Sofradim Production |
Surgical fasteners and methods for sealing wounds
|
|
AU2011231245B2
(en)
|
2010-03-25 |
2015-03-26 |
Covidien Lp |
Medical devices incorporating functional adhesives
|
|
CA2804263A1
(en)
|
2010-06-29 |
2012-01-12 |
Tyco Healthcare Group Lp |
Microwave-powered reactor and method for in situ forming implants
|
|
EP2588153A2
(en)
|
2010-07-01 |
2013-05-08 |
Sofradim Production |
Medical device with predefined activated cellular integration
|
|
EP2598178B1
(en)
|
2010-07-27 |
2018-07-11 |
Sofradim Production |
Polymeric fibers having tissue reactive members
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
WO2012104344A1
(en)
*
|
2011-02-01 |
2012-08-09 |
Genmab A/S |
Human antibodies and antibody-drug conjugates against cd74
|
|
WO2012123269A1
(en)
|
2011-03-11 |
2012-09-20 |
Proyecto De Biomedicina Cima, S.L. |
Immunogenic compositions and methods for their use
|
|
JP6130307B2
(ja)
|
2011-03-17 |
2017-05-17 |
ザ ユニバーシティ オブ バーミンガム |
再指向性免疫療法
|
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
|
WO2012135517A2
(en)
*
|
2011-03-29 |
2012-10-04 |
Immunogen, Inc. |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
RS58367B1
(sr)
|
2011-03-29 |
2019-03-29 |
Immunogen Inc |
Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
|
|
MX2013011201A
(es)
*
|
2011-03-29 |
2013-12-16 |
Immunogen Inc |
Proceso para la elaboracion de conjugados de mejor homogeneidad.
|
|
WO2012138911A2
(en)
*
|
2011-04-05 |
2012-10-11 |
The Administrators Of The Tulane Educational Fund |
Conjugates of anti-hiv drugs and somatostatin analogs
|
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
MX2014004953A
(es)
*
|
2011-11-03 |
2014-05-28 |
Bayer Ip Gmbh |
Ligadores basados en tirosina para la conexion desprendible de peptidos.
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
EP2606897A1
(en)
|
2011-12-22 |
2013-06-26 |
Laboratorios Del. Dr. Esteve, S.A. |
Methods and compositions for the treatment of diseases caused by enveloped viruses
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
KR102557309B1
(ko)
*
|
2012-05-15 |
2023-07-20 |
씨젠 인크. |
자가-안정화 링커 접합체
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
WO2014055877A1
(en)
|
2012-10-04 |
2014-04-10 |
Immunogen, Inc. |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
|
DK2907824T3
(en)
|
2012-10-11 |
2018-07-23 |
Daiichi Sankyo Co Ltd |
ANTIBODY-drug conjugate
|
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US12310958B2
(en)
|
2012-12-13 |
2025-05-27 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US20240139324A1
(en)
|
2012-12-13 |
2024-05-02 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
SI2900277T1
(sl)
|
2012-12-13 |
2022-05-31 |
Immunomedics, Inc. |
Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
|
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
RU2015129800A
(ru)
|
2012-12-21 |
2017-01-30 |
Биоэллаенс К. В. |
Гидрофильные саморазрушающиеся линкеры и их конъюгаты
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9783618B2
(en)
*
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
US9775928B2
(en)
|
2013-06-18 |
2017-10-03 |
Covidien Lp |
Adhesive barbed filament
|
|
AU2014299561B2
(en)
*
|
2013-06-24 |
2017-06-08 |
Ablbio |
Antibody-drug conjugate having improved stability and use thereof
|
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
DE112014004537T5
(de)
|
2013-10-01 |
2016-07-21 |
Kymab Limited |
Tiermodelle und therapeutische Moleküle
|
|
LT3424955T
(lt)
|
2013-12-25 |
2025-06-25 |
Daiichi Sankyo Company, Limited |
Anti-trop2 antikūno ir vaisto konjugato gamybos būdas
|
|
SI3466976T1
(sl)
|
2014-01-31 |
2021-12-31 |
Daiichi Sankyo Company, Limited |
Anti-her2 konjugat protitelesa-zdravila
|
|
WO2015126548A1
(en)
|
2014-02-21 |
2015-08-27 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
|
KR102399277B1
(ko)
|
2014-04-10 |
2022-05-18 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
JP6612738B2
(ja)
|
2014-04-10 |
2019-11-27 |
第一三共株式会社 |
抗ｈｅｒ２抗体−薬物コンジュゲート
|
|
SG11201610620UA
(en)
|
2014-06-20 |
2017-01-27 |
Bioalliance Cv |
Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
|
|
WO2015196089A1
(en)
*
|
2014-06-20 |
2015-12-23 |
Bioalliance C.V. |
Anti-cd22 antibody-drug conjugates and methods of using thereof
|
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
CA2953371C
(en)
*
|
2014-06-30 |
2021-08-24 |
Tarveda Therapeutics, Inc. |
Targeted conjugates and particles and formulations thereof
|
|
CN117138060A
(zh)
|
2014-10-07 |
2023-12-01 |
免疫医疗公司 |
抗体-药物缀合物的新辅助剂用途
|
|
WO2016170541A1
(en)
|
2015-04-21 |
2016-10-27 |
Enlivex Therapeutics Ltd. |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
WO2016172427A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
WO2016191481A1
(en)
|
2015-05-28 |
2016-12-01 |
Immunomedics, Inc. |
T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines
|
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
|
EP4257134A3
(en)
|
2015-06-25 |
2024-01-24 |
Immunomedics, Inc. |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
EP4180455A1
(en)
|
2015-06-29 |
2023-05-17 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
JP7057278B2
(ja)
|
2015-10-28 |
2022-04-19 |
ターベダ セラピューティクス インコーポレイテッド |
Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤
|
|
SG11201805557SA
(en)
|
2016-01-08 |
2018-07-30 |
Bioalliance Cv |
Tetravalent anti-psgl-1 antibodies and uses thereof
|
|
CN115969970A
(zh)
|
2016-02-10 |
2023-04-18 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan的组合
|
|
CN109069539A
(zh)
|
2016-02-18 |
2018-12-21 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
|
JP7379795B2
(ja)
|
2016-04-27 |
2023-11-15 |
イミューノメディクス、インコーポレイテッド |
チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
|
|
MX2019001302A
(es)
|
2016-08-09 |
2019-06-12 |
Seattle Genetics Inc |
Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
|
|
BR112019011794A2
(pt)
|
2016-12-12 |
2019-10-29 |
Daiichi Sankyo Co Ltd |
composição farmacêutica, e, método terapêutico.
|
|
CA3050668C
(en)
|
2017-01-17 |
2023-08-15 |
Daiichi Sankyo Company, Limited |
Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
|
|
KR20240074000A
(ko)
|
2017-02-28 |
2024-05-27 |
다이이찌 산쿄 가부시키가이샤 |
항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법
|
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
|
US10918734B2
(en)
|
2017-03-27 |
2021-02-16 |
Immunomedics, Inc. |
Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
|
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
TW202532102A
(zh)
|
2017-05-15 |
2025-08-16 |
日商第一三共股份有限公司 |
抗體－藥物結合物及其用途
|
|
BR112020003466B1
(pt)
|
2017-08-31 |
2023-12-12 |
Daiichi Sankyo Company, Limited |
Métodos de produção de composto, e, composto
|
|
ES3057444T3
(en)
|
2017-08-31 |
2026-03-02 |
Daiichi Sankyo Co Ltd |
Improved method for producing antibody-drug conjugate
|
|
CN111542324B
(zh)
*
|
2018-02-11 |
2023-09-12 |
四川科伦博泰生物医药股份有限公司 |
细胞毒性剂及其偶联物、其制备方法及用途
|
|
CA3094313A1
(en)
*
|
2018-04-06 |
2019-10-10 |
Seattle Genetics, Inc. |
Camptothecin peptide conjugates
|
|
HUE067382T2
(hu)
|
2018-05-18 |
2024-10-28 |
Daiichi Sankyo Co Ltd |
Anti-MUC1-exatecan antitest-hatóanyag konjugátum
|
|
TWI851577B
(zh)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
喜樹鹼結合物
|
|
TWI846717B
(zh)
|
2018-07-27 |
2024-07-01 |
日商第一三共股份有限公司 |
辨識抗體-藥物結合物之藥物部位的蛋白質
|
|
TW202537643A
(zh)
|
2018-07-31 |
2025-10-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之用途
|
|
KR20210062005A
(ko)
|
2018-09-20 |
2021-05-28 |
다이이찌 산쿄 가부시키가이샤 |
항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료
|
|
JP7561141B2
(ja)
*
|
2019-04-26 |
2024-10-03 |
イミュノジェン・インコーポレーテッド |
カンプトテシン誘導体
|
|
US20220288219A1
(en)
*
|
2019-07-08 |
2022-09-15 |
Mythic Therapeutics, Inc. |
Antigen-binding protein constructs and uses thereof
|
|
KR20230011913A
(ko)
|
2020-03-04 |
2023-01-25 |
버브 테라퓨틱스, 인크. |
표적화된 rna 전달을 위한 조성물 및 방법
|
|
IL299001A
(en)
*
|
2020-06-19 |
2023-02-01 |
Hangzhou Dac Biotech Co Ltd |
Pairings of a cell-binding molecule with camptocin analogs
|
|
EP4178624A2
(en)
|
2020-07-07 |
2023-05-17 |
Bionecure Therapeutics, Inc. |
Maytansinoids as adc payloads and their use for the treatment of cancer
|
|
JPWO2022014698A1
(https=)
|
2020-07-17 |
2022-01-20 |
|
|
|
CN116368226A
(zh)
|
2020-09-04 |
2023-06-30 |
维乎医疗有限公司 |
用于加帽rna的组合物和方法
|
|
US20250073349A1
(en)
|
2021-05-10 |
2025-03-06 |
Kawasaki Institute Of Industrial Promotion |
Antibody having reduced binding affinity for antigen
|
|
JP7673255B2
(ja)
|
2021-06-11 |
2025-05-08 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
|
|
TWI910028B
(zh)
|
2021-06-11 |
2025-12-21 |
美商基利科學股份有限公司 |
Mcl-1抑制劑與抗癌劑之組合
|
|
JP2024530647A
(ja)
|
2021-08-03 |
2024-08-23 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
標的ｒｎａ送達のための組成物および方法
|
|
CN118541392A
(zh)
|
2021-09-28 |
2024-08-23 |
准星生物医药有限公司 |
多种形式的分子复合物
|
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
EP4422756A1
(en)
|
2021-10-29 |
2024-09-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
EP4452415B1
(en)
|
2021-12-22 |
2026-02-25 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
CA3253296A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
|
|
US20250249115A1
(en)
|
2022-04-13 |
2025-08-07 |
Gilead Sciences, Inc. |
Combination therapy for treating tumor antigen expressing cancers
|
|
CN119173276A
(zh)
|
2022-04-13 |
2024-12-20 |
吉利德科学公司 |
用于治疗表达Trop-2的癌症的组合疗法
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
WO2024097812A1
(en)
|
2022-11-04 |
2024-05-10 |
Gilead Sciences, Inc. |
Therapy for treating bladder cancer
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN120882725A
(zh)
|
2023-04-11 |
2025-10-31 |
吉利德科学公司 |
Kras调节化合物
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024248123A1
(ja)
|
2023-06-02 |
2024-12-05 |
第一三共株式会社 |
抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|